The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 528 KB) and Technical Notes (PDF, 794 KB) pages.

Download and Print: Download Printer-friendly PDF Download data

Table 19.31

All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis
All Races, Females, 2009-2015

Site All Ages Ages 0-19 Ages 20-64 Ages 65+
Count Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval
Low High Low High Low High Low High
Lymphoid Neoplasm 81,485 72.1 71.7 72.5 90.8 89.8 91.8 81.3 80.8 81.8 62.1 61.4 62.8
1 Hodgkin Lymphoma 6,512 87.8 86.8 88.8 97.1 95.6 98.1 92.1 91.1 92.9 57.4 52.9 61.6
2 Non-Hodgkin lymphoma 73,067 71.1 70.6 71.5 89.0 87.7 90.2 79.7 79.1 80.2 62.8 62.1 63.5
2(a) Non-Hodgkin lymphoma, B-cell 68,302 71.3 70.8 71.8 89.7 88.3 90.9 80.1 79.5 80.7 63.3 62.6 64.1
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell 3,951 69.6 67.9 71.2 89.7 88.2 91.0 41.9 38.3 45.4 21.1 15.9 26.7
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell 60,381 71.6 71.1 72.1 89.4 85.2 92.5 81.7 81.1 82.3 63.8 63.0 64.6
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma 12,913 83.3 82.2 84.4 100.0 - - 91.3 90.0 92.4 78.9 77.3 80.5
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma 11,666 85.4 84.2 86.6 100.0 - - 93.4 92.1 94.4 81.0 79.3 82.7
2(a) 2.1.2. Prolymphocytic leukemia, B-cell 31 39.6 17.8 60.9 100.0 - - 34.9 1.3 77.4 33.4 10.8 58.3
2(a) 2.1.3. Mantle-cell lymphoma 1,216 64.2 60.3 67.8 - - - 72.5 67.0 77.3 59.2 53.8 64.2
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglubulinemia 1,286 85.5 81.7 88.6 100.0 - - 90.8 86.4 93.8 82.4 76.8 86.7
2(a) 2.2.1. Lymphoplasmacytic lymphoma 610 84.0 78.4 88.3 100.0 - - 86.4 79.6 91.0 82.0 73.4 88.0
2(a) 2.2.2. Waldenstrom macroglubulinemia 676 86.8 81.1 90.8 - - - 94.9 88.2 97.8 82.6 74.7 88.3
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL) 15,762 63.2 62.2 64.1 87.2 80.7 91.6 76.1 74.9 77.3 53.1 51.6 54.5
2(a) 2.3.1. DLBCL, NOSc 15,450 62.8 61.8 63.7 86.8 79.9 91.4 75.6 74.4 76.8 53.1 51.6 54.5
2(a) 2.3.2. Intravascular large B-cell lymphoma 42 57.5 39.5 71.9 - - - 56.1 30.1 75.8 57.0 32.3 75.6
2(a) 2.3.3. Primary effusion lymphoma 5 - - - - - - - - - 0.0 - -
2(a) 2.3.4. Mediastinal large B-cell lymphoma 265 88.1 82.8 91.8 91.7 53.8 98.8 89.9 84.5 93.5 37.4 9.5 66.3
2(a) 2.4. Burkitt lymphoma/leukemia 583 60.6 56.0 64.9 92.1 84.2 96.2 59.6 53.3 65.3 36.4 28.2 44.7
2(a) 2.5. Marginal-zone lymphoma (MZL) 5,391 91.6 90.1 92.9 94.8 68.0 99.2 95.4 93.9 96.5 88.3 85.6 90.5
2(a) 2.5.1. Splenic MZL 446 89.3 83.9 93.0 - - - 93.0 85.3 96.7 86.3 79.1 91.1
2(a) 2.5.2. Extranodal MZL, MALTc type 3,425 94.2 92.4 95.6 93.8 63.2 99.1 96.3 94.6 97.5 91.9 88.4 94.4
2(a) 2.5.3. Nodal MZL 1,520 86.2 83.0 88.8 100.0 - - 93.2 89.7 95.6 80.7 75.6 84.8
2(a) 2.6. Follicular lymphoma 8,770 88.4 87.3 89.5 90.1 46.9 98.6 94.0 92.9 94.9 82.0 79.8 83.9
2(a) 2.7. Hairy-cell leukemia 314 91.1 84.8 94.9 - - - 97.5 93.0 99.1 76.4 60.6 86.6
2(a) 2.8. Plasma cell neoplasms 15,354 52.3 51.2 53.4 75.6 32.4 93.3 65.7 64.2 67.2 43.0 41.5 44.5
2(a) 2.8.1. Plasmacytoma 795 72.7 68.1 76.6 85.7 33.4 97.9 83.2 77.7 87.5 59.9 52.7 66.3
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia 14,559 51.2 50.1 52.3 0.0 - - 64.4 62.8 66.0 42.2 40.7 43.7
2(a) 2.9. Heavy chain disease 8 63.8 22.7 87.3 - - - - - - 41.4 5.1 77.0
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOSc 3,970 69.2 67.0 71.2 87.7 59.0 96.8 82.6 79.8 85.0 62.6 59.7 65.4
2(b) Non-Hodgkin lymphoma, T-cell 4,550 67.4 65.7 69.1 85.4 81.4 88.7 75.1 73.1 77.0 51.5 48.2 54.6
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell 56 67.9 53.7 78.7 91.7 70.6 97.9 62.0 39.2 78.3 - - -
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell 4,487 67.4 65.7 69.1 85.0 80.8 88.4 75.3 73.2 77.2 51.6 48.3 54.8
2(b) 2.1. Mycosis fungoides/Sezary syndrome 1,213 92.8 89.8 94.9 100.0 - - 96.0 93.2 97.6 86.0 78.5 91.0
2(b) 2.1.1. Mycosis fungoides 1,171 94.5 91.5 96.5 100.0 - - 97.4 94.5 98.7 88.3 80.4 93.1
2(b) 2.1.2. Sezary syndrome 42 38.2 20.7 55.5 - - - 39.6 14.8 63.9 35.5 13.1 59.0
2(b) 2.2. Peripheral T-cell lymphoma 2,474 60.4 58.0 62.7 88.5 80.3 93.4 71.5 68.5 74.2 43.6 39.6 47.5
2(b) 2.2.1. Peripheral T-cell lymphoma, NOSc 851 39.5 35.5 43.5 56.6 26.8 78.2 51.9 46.2 57.2 27.7 22.3 33.3
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma 343 41.1 34.6 47.5 - - - 60.4 49.7 69.5 30.1 22.4 38.1
2(b) 2.2.3. Subcutaneous panniculitis- like T-cell lymphoma 54 91.7 75.0 97.4 100.0 - - 86.0 63.9 95.0 100.0 - -
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type 430 72.8 67.6 77.3 91.0 79.4 96.2 77.7 71.4 82.7 46.3 36.1 55.9
2(b) 2.2.5. Hepatosplenic T-cell lymphoma 21 12.6 1.0 39.2 - - - 12.7 1.0 39.5 - - -
2(b) 2.2.6. Enteropathy-type T-cell lymphoma 31 8.6 1.6 23.5 - - - 0.0 - - 13.5 2.3 34.3
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOSc 512 84.6 79.4 88.5 100.0 - - 89.4 83.9 93.1 74.9 64.2 82.9
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma 232 89.5 81.2 94.3 92.3 56.6 98.9 93.2 85.6 96.8 82.0 60.8 92.4
2(b) 2.3. Adult T-cell leukemia/lymphoma 525 59.6 54.5 64.3 81.7 75.7 86.4 47.7 39.4 55.6 23.5 12.8 36.1
2(b) 2.4. NKc/T-cell lymphoma, nasal-type/ agressive NKc-cell leukemia 182 42.6 34.3 50.6 - - - 47.6 38.0 56.5 29.8 14.9 46.2
2(b) 2.5. T-cell large granular lymphocytic leukemia 16 66.3 30.8 86.7 - - - 85.8 33.1 97.9 44.9 7.9 77.7
2(b) 2.6. Prolymphocytic leukemia, T-cell 77 11.1 4.1 21.8 - - - 23.8 8.9 42.7 0.0 - -
2(b) 3. Non-Hodgkin lymphoma, NOSc , T-cell 7 57.4 17.1 84.0 - - - 50.1 11.1 80.5 100.0 - -
2(c) Non-Hodgkin lymphoma, unknown lineage 215 57.6 49.6 64.8 90.2 72.3 96.7 56.7 44.1 67.5 46.9 35.3 57.7
2(c) 1. Precursor lymphoblastic leukemia/ lymphoma, unknown lineage 69 70.5 57.3 80.2 90.2 72.3 96.7 56.5 34.6 73.6 34.1 7.9 63.5
2(c) 2. Prolymphocytic leukemia, unknown lineage 9 22.8 3.4 52.4 - - - - - - 22.8 3.4 52.4
2(c) 3. Non-Hodgkin lymphoma, NOSc, unknown lineage 137 53.1 42.7 62.5 - - - 56.8 41.1 69.8 50.1 36.9 61.9
2(*) 1. Total precursor lymphoma/leukemiad 4,076 69.6 68.0 71.2 89.7 88.2 91.0 42.9 39.5 46.3 21.5 16.5 27.0
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma 127 69.6 57.1 79.1 - - - 83.2 68.5 91.5 52.4 31.4 69.7
4 Lymphoid neoplasm, NOSc 1,779 54.2 51.3 57.1 86.3 70.8 93.9 75.8 71.7 79.3 41.2 37.3 45.1

Footnotes:

a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD.  Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Page Navigation: << Previous Next >>

The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.